Michael P. Dube Sells 1,372 Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) Stock

Intellia Therapeutics, Inc. (NASDAQ:NTLA) CAO Michael P. Dube sold 1,372 shares of the business’s stock in a transaction that occurred on Friday, January 3rd. The shares were sold at an average price of $12.18, for a total value of $16,710.96. Following the completion of the transaction, the chief accounting officer now owns 45,640 shares of the company’s stock, valued at $555,895.20. This represents a 2.92 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this link.

Intellia Therapeutics Trading Down 2.6 %

NASDAQ NTLA opened at $12.47 on Wednesday. The firm has a market capitalization of $1.27 billion, a P/E ratio of -2.29 and a beta of 1.83. The firm’s fifty day moving average price is $14.01 and its two-hundred day moving average price is $19.28. Intellia Therapeutics, Inc. has a 1 year low of $11.34 and a 1 year high of $34.87.

Intellia Therapeutics (NASDAQ:NTLA) last issued its earnings results on Thursday, November 7th. The company reported ($1.34) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.37) by $0.03. The firm had revenue of $9.10 million during the quarter, compared to the consensus estimate of $8.28 million. During the same period in the previous year, the company posted ($1.38) earnings per share. The firm’s revenue for the quarter was down 24.1% compared to the same quarter last year. On average, research analysts anticipate that Intellia Therapeutics, Inc. will post -5.12 EPS for the current fiscal year.

Analyst Ratings Changes

NTLA has been the subject of several research analyst reports. Robert W. Baird reduced their price target on shares of Intellia Therapeutics from $24.00 to $18.00 and set a “neutral” rating for the company in a report on Friday, October 25th. Royal Bank of Canada reiterated an “outperform” rating and set a $54.00 target price on shares of Intellia Therapeutics in a report on Thursday, September 19th. StockNews.com raised Intellia Therapeutics to a “sell” rating in a research note on Friday, November 8th. Oppenheimer reduced their price objective on Intellia Therapeutics from $70.00 to $60.00 and set an “outperform” rating for the company in a research report on Monday, November 11th. Finally, William Blair reissued a “neutral” rating and issued a $14.00 target price on shares of Intellia Therapeutics in a research report on Monday, November 18th. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $54.94.

Institutional Trading of Intellia Therapeutics

A number of hedge funds have recently made changes to their positions in the business. Bank of New York Mellon Corp raised its stake in Intellia Therapeutics by 0.6% in the 2nd quarter. Bank of New York Mellon Corp now owns 364,306 shares of the company’s stock valued at $8,153,000 after acquiring an additional 2,301 shares during the period. Rhumbline Advisers lifted its stake in shares of Intellia Therapeutics by 5.3% during the 2nd quarter. Rhumbline Advisers now owns 175,335 shares of the company’s stock worth $3,924,000 after buying an additional 8,797 shares during the last quarter. Arizona State Retirement System boosted its holdings in shares of Intellia Therapeutics by 9.7% during the 2nd quarter. Arizona State Retirement System now owns 25,648 shares of the company’s stock worth $574,000 after buying an additional 2,267 shares during the period. American Century Companies Inc. grew its stake in Intellia Therapeutics by 23.8% in the 2nd quarter. American Century Companies Inc. now owns 330,514 shares of the company’s stock valued at $7,397,000 after buying an additional 63,550 shares during the last quarter. Finally, Federated Hermes Inc. raised its holdings in Intellia Therapeutics by 19.2% in the 2nd quarter. Federated Hermes Inc. now owns 2,300,889 shares of the company’s stock valued at $51,494,000 after acquiring an additional 371,189 shares during the period. 88.77% of the stock is owned by institutional investors and hedge funds.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.